Patients with psoriasis appear to be at greater risk for developing colorectal cancer, suggests a recent study, noting how gastroenterology consultation and colonoscopic examination are indicated for such individuals presenting with bowel symptoms.
People who have never smoked in their lives still run the risk of developing lung cancer, and among Chinese women in Singapore, this risk is attributed to a history of lung cancer in the immediate family.
Six months of adjuvant trastuzumab treatment is noninferior to the standard of care (SoC) of 12 months in patients with HER2-positive early-stage breast cancer, according to results from an individual patient data (IPD) meta-analysis of five noninferiority randomized controlled trials (RCTs) presented at the European Society for Medical Oncology (ESMO) Congress 2021.
Obese people are more likely to develop early-onset colorectal cancer (CRC), suggests a study, noting that the increasing prevalence of obesity in younger generations may significantly contribute to the increase in this disease.
Aspirin safely lowers the risk of hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients suffering from a heavy burden of metabolic risk, according to a study presented at The Liver Meeting Digital Experience 2021 of the American Association for the Study of Liver Diseases (AASLD 2021).
Adding daratumumab to backbone treatments against multiple myeloma (MM) yields high clinical efficacy and has an acceptable toxicity profile, a recent study has found. Such regimens are good treatment options for newly diagnosed (ND) and relapsed/refractory (RR) MM.
Fusion biopsy with magnetic resonance imaging and ultrasonography (MRI/US) is an efficient method of detecting clinically significant prostate cancer (csPCa) in biopsy-naïve men with prostate specific antigen (PSA) levels 4–10 ng/mL, a new study has found.
The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.